Brad H Rovin

List of Publications by Citations

Source: https://exaly.com/author-pdf/305667/brad-h-rovin-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124 papers	4,544 citations	34 h-index	65 g-index
146 ext. papers	6,734 ext. citations	7.1 avg, IF	6.02 L-index

#	Paper	IF	Citations
124	Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis and Rheumatism*, **2012**, 64, 1215-26		796
123	Update on Lupus Nephritis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 825-835	8.3	339
122	Urine chemokines as biomarkers of human systemic lupus erythematosus activity. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 467-73	12.7	211
121	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. *New England Journal of Medicine*, **2020**, 383, 1117-1128	59.2	175
120	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. *New England Journal of Medicine*, **2019**, 381, 36-46	59.2	169
119	Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. *Arthritis and Rheumatology*, **2015**, 67, 1305-13	9.5	146
118	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2019**, 95, 268-280	9.9	145
117	A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney International*, **2019**, 95, 219-231	9.9	116
116	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1306-1313	12.7	111
115	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney International*, **2021**, 100, S1-S276	9.9	91
114	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney International*, **2019**, 95, 281-295	9.9	87
113	Histologic versus clinical remission in proliferative lupus nephritis. *Nephrology Dialysis Transplantation*, **2017**, 32, 1338-1344	4.3	86
112	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. *Lupus Science and Medicine*, **2015**, 2, e000123	4.6	86
111	Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. *Annals of the Rheumatic Diseases*, **2018**, 77, 911-913	2.4	79
110	Update on Lupus Nephritis: Core Curriculum 2020. *American Journal of Kidney Diseases*, **2020**, 76, 265-281	7.4	76
109	Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. *Nephrology Dialysis Transplantation*, **2014**, 29, 2228-34	4.3	73
108	Lupus nephritis: the evolving role of novel therapeutics. *American Journal of Kidney Diseases*, **2014**, 63, 677-90	7.4	71

107	MG53-mediated cell membrane repair protects against acute kidney injury. *Science Translational Medicine*, **2015**, 7, 279ra36	17.5	70
106	Biomarkers for lupus nephritis: the quest continues. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1858-65	6.9	70
105	Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 279-84	6.9	58
104	A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. *Kidney International*, **2018**, 94, 788-794	9.9	56
103	Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. *Kidney International*, **2020**, 98, 233-234	9.9	55
102	Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 2070-2080	40	55
101	Biomarker discovery in human SLE nephritis. *Bulletin of the NYU Hospital for Joint Diseases*, **2007**, 65, 187-93		53
100	Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. *Clinical Chemistry*, **2017**, 63, 1515-1526	5.5	51
99	Staphylococcus-related glomerulonephritis and poststreptococcal glomerulonephritis: why defining "post" is important in understanding and treating infection-related glomerulonephritis. *American Journal of Kidney Diseases*, **2015**, 65, 826-32	7.4	49
98	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. *Kidney International*, **2021**, 100, 753-779	9.9	46
97	A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. *Kidney International*, **2016**, 90, 493-501	9.9	44
96	Lupus community panel proposals for optimising clinical trials: 2018. *Lupus Science and Medicine*, **2018**, 5, e000258	4.6	43
95	Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. *Kidney International*, **2021**, 99, 1487	9.9	42
94	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. *Arthritis Care and Research*, **2016**, 68, 1003-11	4.7	42
93	Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 39-49	6.9	39
92	Hurdles to the introduction of new therapies for immune-mediated kidney diseases. *Nature Reviews Nephrology*, **2016**, 12, 205-16	14.9	37
91	Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 147-53	6.9	36
90	Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 47-53	6.9	34

89	Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. *Lupus Science and Medicine*, **2015**, 2, e000112	4.6	32
88	Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. *Nephrology Dialysis Transplantation*, **2017**, 32, i71-i79	4.3	31
87	Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. *Proteomics - Clinical Applications*, **2015**, 9, 1012-20	3.1	31
86	New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. *Arthritis and Rheumatology*, **2017**, 69, 487-493	9.5	30
85	Cyclopentenone prostaglandins inhibit cytokine-induced nf-kappab activation and chemokine production by human mesangial cells. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 1659-1667	12.7	28
84	Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy. *Kidney Research and Clinical Practice*, **2017**, 36, 387-392	3.6	27
83	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 1595-1602	6.9	27
82	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. *Arthritis and Rheumatology*, **2019**, 71, 411-419	9.5	25
81	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 673-684	6.9	24
80	Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. *Kidney International*, **2020**, 97, 156-162	9.9	24
79	Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 1335-1347	12.7	24
78	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. *Kidney International Reports*, **2019**, 4, 1152-1160	4.1	23
77	A multimodal and integrated approach to interrogate human kidney biopsies with rigor and reproducibility: guidelines from the Kidney Precision Medicine Project. *Physiological Genomics*, **2021** , 53, 1-11	3.6	21
76	The kidney biopsy in lupus nephritis: is it still relevant?. *Rheumatic Disease Clinics of North America*, **2014**, 40, 537-52, ix	2.4	20
75	B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. *Annals of the Rheumatic Diseases*, **2021**,	2.4	19
74	B-cell therapy in lupus nephritis: an overview. *Nephrology Dialysis Transplantation*, **2019**, 34, 22-29	4.3	18
73	Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. *Translational Research*, **2017**, 182, 1-13	11	18
72	Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. *Nephrology Dialysis Transplantation*, **2020**, 35, 2123-2129	4.3	18

71	Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2016**, 68, 195-202	4.7	17
70	Can we personalize treatment for kidney diseases?. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1670-6	6.9	15
69	Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?. *American Journal of Hypertension*, **2015**, 28, 182-9	2.3	13
68	Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. *Nephrology Dialysis Transplantation*, **2019**, 34, 1197-1206	4.3	13
67	The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future. *Advances in Chronic Kidney Disease*, **2019**, 26, 360-368	4.7	13
66	Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. *Nephrology Dialysis Transplantation*, **2018**, 33, 1168-1175	4.3	11
65	Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). *Kidney International Reports*, **2019**, 4, 1633-1637	4.1	10
64	Of mice and men: the relevance of the mouse to the study of human SLE. *Immunologic Research*, **2001**, 24, 211-24	4.3	10
63	Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy. *Transplantation*, **2019**, 103, e52-e53	1.8	10
62	Molecular characterization of the human kidney interstitium in health and disease. *Science Advances*, **2021**, 7,	14.3	9
61	A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. *Kidney International*, **2021**,	9.9	9
60	Rethinking Lupus Nephritis Classification on a Molecular Level. *Journal of Clinical Medicine*, **2019**, 8,	5.1	8
59	Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis. *Kidney International Reports*, **2020**, 5, 1066-1068	4.1	8
58	Induction Therapy for Lupus Nephritis: the Highlights. *Current Rheumatology Reports*, **2018**, 20, 60	4.9	8
57	Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?. *Nephron Clinical Practice*, **2011**, 117, c8-14		8
56	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.. *Annals of the Rheumatic Diseases*, **2022**,	2.4	8
55	The lupus nephritis management renaissance. *Kidney International*, **2021**,	9.9	8
54	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. *Lupus Science and Medicine*, **2019**, 6, e000342	4.6	8

53	The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1394-1398	12.7	7
52	Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. *Kidney Medicine*, **2019**, 1, 51-56	2.8	7
51	Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. *Kidney International Reports*, **2018**, 3, 1057-1063	4.1	7
50	MG53 protects against contrast-induced acute kidney injury by reducing cell membrane damage and apoptosis. *Acta Pharmacologica Sinica*, **2020**, 41, 1457-1464	8	6
49	Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. *Arthritis and Rheumatology*, **2021**, 73, 244-254	9.5	6
48	Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. *Arthritis Care and Research*, **2021**, 73, 146-157	4.7	6
47	Targeting B-cells in lupus nephritis: should cautious optimism remain?. *Nephrology Dialysis Transplantation*, **2013**, 28, 7-9	4.3	5
46	Advances and Challenges on New Therapies and Clinical Targets of Acute Kidney Injury. *Toxicologic Pathology*, **2018**, 46, 925-929	2.1	5
45	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *American Journal of Kidney Diseases*, **2021**,	7.4	5
44	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. *Lupus Science and Medicine*, **2019**, 6, e000308	4.6	4
43	Application of Laser Microdissection to Uncover Regional Transcriptomics in Human Kidney Tissue. *Journal of Visualized Experiments*, **2020**,	1.6	4
42	Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. *CKJ: Clinical Kidney Journal*, **2015**, 8, 492-502	4.5	4
41	Beyond anemia: hepcidin, monocytes and inflammation. *Biological Chemistry*, **2013**, 394, 1-10	4.5	4
40	Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis. *Kidney International Reports*, **2020**, 5, 1228-1239	4.1	3
39	A78: Urine Biomarkers Role in Predicting the Future Development of Renal Functional Loss With Lupus Nephritis in Children and Adults. *Arthritis and Rheumatology*, **2014**, 66, S111-S111	9.5	3
38	Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Nephrology (Saint-Petersburg)*, **2021** , 25, 96-119	0.4	3
37	Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
36	Bath salts: a newly recognized cause of acute kidney injury. *Case Reports in Nephrology*, **2012**, 2012, 560858	5.8	2

35	A reference tissue atlas for the human kidney		2
34	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. *Kidney International Reports*, **2020**, 5, 1302-1305	4.1	2
33	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. *Thrombosis Research*, **2021**, 201, 50-59	8.2	2
32	Response to: Lack of standardization of ANA and implications for drug development and precision medicineby Mahler. *Annals of the Rheumatic Diseases*, **2019**, 78, e34	2.4	2
31	A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis. *Frontiers in Immunology*, **2021**, 12, 621039	8.4	2
30	Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
29	LB001EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL. *Nephrology Dialysis Transplantation*, **2020**, 35,	4.3	1
28	Response to: Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunitiesby Bossuyt. *Annals of the Rheumatic Diseases*, **2019**, 78, e77	2.4	1
27	Prediction Models of Treatment Response in Lupus Nephritis. *Kidney International*, **2021**,	9.9	1
26	A tolvaptan skeptic repents. *Kidney International*, **2020**, 98, 293	9.9	1
25	Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients. *Scientific Reports*, **2020**, 10, 20202	4.9	1
24	MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS. *Nephrology Dialysis Transplantation*, **2021**, 36,	4.3	1
23	Response to: Variation in antinuclear antibody detection by automated indirect immunofluorescence analysisby van Hoovels. *Annals of the Rheumatic Diseases*, **2019**, 78, e49	2.4	1
22	Response to Antinuclear antibodies by indirect immunofluorescence and solid phase assaysby Bossuyt. *Annals of the Rheumatic Diseases*, **2020**, 79, e66	2.4	1
21	Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy. *Kidney International Reports*, **2021**, 6, 2653-2660	4.1	1
20	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. *Kidney International*, **2021**, 100, 881-893	9.9	1
19	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. *American Journal of Physiology - Renal Physiology*, **2021**, 321, F505-F516	4.3	1
18	A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops.. *Clinical Journal of the American Society of Nephrology: CJASN*, **2021**,	6.9	1

17	Membranoproliferative Glomerulonephritis With Changing Immunofluorescence Pattern.. *Kidney International Reports*, **2022**, 7, 1123-1127	4.1	0
16	The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy. *Kidney International*, **2021**, 99, 811-813	9.9	0
15	The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. *Kidney International Reports*, **2021**, 6, 2105-2113	4.1	0
14	Reply. *Arthritis and Rheumatology*, **2017**, 69, 1507-1508	9.5	
13	The authors reply. *Kidney International*, **2019**, 95, 992-993	9.9	
12	Letter to the Editor. *Kidney International Reports*, **2020**, 5, 2121	4.1	
11	Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab. *Kidney International Reports*, **2020**, 5, 951-954	4.1	
10	Urine inositol pentakisphosphate 2-kinase and changes in kidney structure in early diabetic kidney disease in type 1 diabetes. *American Journal of Physiology - Renal Physiology*, **2018**, 315, F1484-F1492	4.3	
9	Response to: Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center studyby Pregnalato. *Annals of the Rheumatic Diseases*, **2019**, 78, e51	2.4	
8	Reply. *Arthritis and Rheumatology*, **2017**, 69, 2247-2248	9.5	
7	Variability in the B cell-receptor repertoire across immune-mediated diseases. *Kidney International*, **2020**, 98, 536-538	9.9	
6	The authors reply. *Kidney International*, **2021**, 99, 1242	9.9	
5	Response to: Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?by Meroni. *Annals of the Rheumatic Diseases*, **2019**, 78, e47	2.4	
4	Response to: ANA testing in "real life"by Infantino. *Annals of the Rheumatic Diseases*, **2020**, 79, e4	2.4	
3	Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco. *Annals of the Rheumatic Diseases*, **2020**, 79, e7	2.4	
2	Response to: Can solid-phase assays replace immunofluorescence for ANA screening?by Bizzaro. *Annals of the Rheumatic Diseases*, **2020**, 79, e33	2.4	
1	The authors reply. *Kidney International*, **2020**, 97, 807	9.9	